|
Acute GVH disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Collectively, we found that + 7 days B7H1/B7H3 serum levels can predict grade III-IV aGVHD, while only the + 7 days B7H1 serum level, together with viral infection and donor age, could independently predict GRM in patients with haplo-HSCT.
|
30725359 |
2019 |
|
Acute leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Owing to the expression of B7-H3 being statistically relevant in predicting disease progression and a shorter life survival, our results demonstrated that B7-H3 expression in acute leukemia predicts an unfavorable outcome.
|
25130683 |
2015 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression in squamous cell carcinoma (SCC) was significantly higher than those in adenocarcinoma (p=0.048), while CD133 expression in large cell lung carcinoma was higher than that in SCC (p=0.023).
|
20844808 |
2010 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Immunostaining was also performed to compare expression of programmed death ligand 1 (PD-L1) and B7-H3 in IMA and conventional adenocarcinomas.
|
30513627 |
2018 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
KRAS-mutant ADC specimens showed higher expression of PD-L1 in MCs and of B7-H3, T-cell immunoglobulin mucin family member 3, and IDO-1 in TAICs than wild type.
|
29526824 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis showed that CD276 expression level had a significant effect on OS of patients with lung adenocarcinoma, while in squamous cell carcinoma its expression level had no significant effect on OS.
|
31737785 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we used logistic regression analysis to examine the correlations between B7-H3 expression levels and clinicopathological/molecular features of lung adenocarcinoma.
|
28024695 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
The Cox regression analysis showed that B7-H3 might serve as an independent prognostic marker of lung adenocarcinoma.
|
30127617 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggested that B7-H3 may be a potential therapeutic target for AdCC.
|
28386362 |
2017 |
|
Adenoid cystic carcinoma of salivary gland
|
0.010 |
Biomarker
|
disease |
BEFREE |
B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway.
|
28386362 |
2017 |
|
Adult Craniopharyngioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results revealed B7-H3 was highly expressed in CPs and targeting B7-H3 might therefore be an effective therapeutic strategy against craniopharyngioma.
|
31043272 |
2019 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.
|
31485480 |
2019 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
To characterize B7H3 in glioblastoma, we conduct analyses not only in glioma cell lines and glioma-initiating cells but also in human glioma tissue specimens.
|
22080438 |
2012 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
|
31466914 |
2019 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma.
|
30914782 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study highlights B7-H3 as a viable target in MB angiogenesis, and that the expression of miR-29 can inhibit B7-H3 and sensitize MB cells to treatment with MYC-inhibiting drugs.
|
31382461 |
2019 |
|
Adult Meningioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we report for the first time the expression profiles of immune checkpoint proteins PD-L2, B7-H3 and CTLA-4 in meningioma and their association to common gene mutations.
|
30546952 |
2019 |
|
Adult Meningioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
B7-H3 was detected with different degrees in all meningioma specimens, predominantly on tumor cell membranes and in cytoplasm.
|
31629137 |
2020 |
|
Advanced breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD276-expressing CEC were significantly higher in 15 patients with advanced colorectal cancer (median 9 (range 1-293 cell per 4 ml); P<0.005), in 83 patients with a glioblastoma multiforme (median 10 (range 0-804); P<0.0001) and in 14 patients with advanced breast cancer (median 14 (range 0-390) P<0.05) as compared with 24 healthy individuals (median 3 (range 0-11)).
|
24892449 |
2014 |
|
Allergic asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of miR-29c/B7-H3 axis in children with allergic asthma.
|
30075787 |
2018 |
|
Ankylosing spondylitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Upregulated B7-H3 protein may play a role in the pathogenesis of AS by binding its receptor on T cells.
|
25567370 |
2015 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results provide evidence for the efficacy of B7-H3 targeted RIT against preclinical models of pancreatic ductal adenocarcinoma (PDAC) and support future studies with <sup>212</sup>Pb-376.96 in combination with chemotherapy to potentiate efficacy against PDAC.
|
29413459 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we showed that B7-H3 acted as a negative prognostic biomarker in PDAC and promoted cell proliferation, invasion and metastasis in pancreatic cancer.
|
30664982 |
2019 |
|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results indicated an important role for B7-H3 in the development of Th1 and Th2 cells in a murine model of asthma and its proinflammatory effects are not dependent on TLR2 signaling.
|
28094276 |
2017 |
|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Level of B7-H3 in asthma exacerbation subjects with inhaled corticosteroid (ICS) treatment recently was significantly lower than subjects without ICS treatment (t = 2.706; p = 0.0136).
|
26108069 |
2016 |